Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Lilly said it would report data from another trial for the pill for weight management later in the year. It plans to file for ...

The pharmaceuticals company says a trial of the pill showed it was similarly safe to injectable weight-loss drugs.

Eli Lilly's Phase 3 study highlights the effectiveness of Orforglipron in lowering blood sugar and promoting weight loss, potentially offering a convenient alternative to GLP-1 injections.

Orforglipron, an oral GLP-1 receptor agonist developed by Eli Lilly, has shown positive Phase 3 results in treating type 2 ...